Leap Therapeutics to Participate at the 43rd Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass. , Jan. 6, 2025 /PRNewswire/ -- Leap Therapeutics, Inc.

(Nasdaq: LPTX ), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E. Onsi , President and Chief Executive Officer, will present a corporate overview at the 43 rd Annual J.P.



Morgan Healthcare Conference in San Francisco, CA. Leap Presentation Details: 43 rd Annual J.P.

Morgan Healthcare Conference Date: Wednesday, January 15, 2025 Time: 2:15 p.m. Pacific Time A live webcast of the presentation may be accessed on the Investors page of the company's website at https://investors.

leaptx.com/ , where a replay of the events will also be available for a limited time. About Leap Therapeutics Leap Therapeutics (Nasdaq: LPTX ) is focused on developing targeted and immuno-oncology therapeutics.

Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. DKN-01 is being developed in patients with esophagogastric, colorectal, and gynecological cancers. Leap's pipeline also includes FL-501, a humanized monoclonal antibody targeting the growth and differentiation factor 15 (GDF-15) protein, in preclinical development.

For more information about Leap Therapeutics, visit http://www.leaptx.com or view our public filings with the SEC that are available via EDGAR at http://www.

sec.gov or via https://investors.leaptx.

com/ . CONTACT: Douglas E. Onsi President & Chief Executive Officer Leap Therapeutics, Inc.

617-714-0360 [email protected] Matthew DeYoung Investor Relations Argot Partners 212-600-1902 [email protected] SOURCE Leap Therapeutics, Inc..